Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02149901 · ClinicalTrials.gov registry record · Early Phase 1

Water and Sudafed in Autonomic Failure

A Early Phase 1 study, sponsored by Vanderbilt University.

Terminated
Registry status
Early Phase 1
Development phase
35
Enrollment target

NCT02149901: Clinical Trial Early Phase 1 study, sponsored by Vanderbilt University.

NCT02149901 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 35 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02149901, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.

TERMINATED
Registry status
Early Phase 1
Development phase
35 participants
Enrollment target

Study Summary

The specific aim of this study is to determine whether water ingestion potentiates the pressor response to pseudoephedrine in patients with primary disorders of autonomic failure. The study design will enable us to also evaluate the pressor response to water alone and to pseudoephedrine alone. In a secondary analysis, we will compare the results in patients with two autonomic disorders, pure autonomic failure (PAF) and multiple system atrophy (MSA). We hypothesize that drinking water following a dose of pseudoephedrine will lead to a greater increase in blood pressure than pseudoephedrine alone.

Interventions

  • DRUG Pseudoephedrine + 480 ml water
  • DRUG Pseudoephedrine + 50 ml water
  • OTHER Placebo + 480 ml water (optional)
  • OTHER Placebo + 50 ml water (optional)

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2014-10
Est. Completion 2020-12
Phase Early Phase 1
Vanderbilt University

430 total trials

Why NCT02149901 stopped before completion

NCT02149901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (34% lower).

The record links to 0 conditions, and to 4 interventions - of which Pseudoephedrine + 480 ml water is the first listed.

NCT02149901 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02149901 about?

NCT02149901 is a clinical study titled "Water and Sudafed in Autonomic Failure". The specific aim of this study is to determine whether water ingestion potentiates the pressor response to pseudoephedrine in patients with primary disorders of autonomic failure. The study design will enable us to also evaluate the pressor response to water alone and to pseudoephedrine alone. In a ...

What is the current status of trial NCT02149901?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 35 participants. The study started on 2014-10. Estimated completion is 2020-12.

What interventions are being tested in trial NCT02149901?

The interventions under investigation include: Pseudoephedrine + 480 ml water (DRUG), Pseudoephedrine + 50 ml water (DRUG), Placebo + 480 ml water (optional) (OTHER), Placebo + 50 ml water (optional) (OTHER).

Who is sponsoring clinical trial NCT02149901?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02149901's enrollment target sits among peer trials

35 735th of 2000 higher than 1,253 of 2,000 other Early Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02149901, the US trial registry maintained by the National Library of Medicine. NCT02149901 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.